Background
==========

Liver cancer is the fifth most common cancer in men and the seventh most common in women, and hepatocellular carcinoma (HCC) is diagnosed in more than half a million of these liver cancer patients worldwide each year \[[@B1]\]. Despite intensive research, the prognosis of HCC remains poor, with an overall 5-year survival rate of approximately 26% in the United States \[[@B2]\]. There is a pressing need for novel biomarkers to identify the subset of patients with a high risk of recurrence and/or poor survival outcomes.

In the current cancer research landscape, epigenetics is a promising and expanding field \[[@B3]-[@B6]\]. DNA methylation, an important pattern of epigenetics, was historically believed to be a relatively stable chromatin modification, but the detection of the presence of 5-hmC facilitated a breakthrough in the field of epigenetic research \[[@B7],[@B8]\]. 5-hmC, also known as the "sixth base", was identified as an oxidant product of 5-methylcytosine (5mC) via the ten-eleven translocation (TET) family, which consists of TET1, -2, and -3. 5-hmC is abundant in embryonic stem (ES) cells and adult neural cells \[[@B8]-[@B10]\]. Currently, the biological prevalence of 5-hmC in cancer remains elusive. Lian et al. reported that the loss of 5-hmC was an epigenetic characteristic of melanoma with diagnostic and prognostic efficiency \[[@B11]\]. 5-hmC levels were high in low-grade tumors and decreased in malignant glioma \[[@B12]\]. Regarding gastroenteric tumors, 5-hmC was decreased in colorectal cancer (CRC) and gastric cancer \[[@B13]\]. In liver cancer, 5-hmC was also decreased compared with the surrounding normal tissue \[[@B14]-[@B16]\].

Isocitrate dehydrogenases (IDHs) catalyze the oxidative decarboxylation of isocitrate, which converts isocitrate to α-ketoglutarate (KG). The IDHs include IDH1 in the cytoplasm and IDH2 in the mitochondria, which catalyze an identical reaction \[[@B17]\] (Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1). IDH1 and IDH2 mutations widely occur in gliomas and acute myeloid leukemia \[[@B18]-[@B21]\], leading to the production of 2-hydroxyglutarate (2-HG), which inhibits multiple α-KG-dependent dioxygenases, including the TET family of 5-mC hydroxylases (which results in decreased 5-hmC) \[[@B22]\]. Lian et al. found that IDH2 was significantly downregulated in melanoma \[[@B11]\]. However, 5-hmC and IDH2 expression in HCC have yet to be characterized in a large series of tumors with documented clinical, pathological, and molecular information.

In this study, we sought to determine the clinical relevance of 5-hmC and IDH2 protein expression in a large series of surgically resected HCCs using two cohorts. We studied the association between these two proteins and tumor history, as well as the patients' clinical-pathologic features, including age, sex, stage, overall survival (OS), and time to recurrence (TTR). We found that combined 5-hmC and IDH2 protein expression was an independent prognostic factor for HCC patients after surgery.

Materials and methods
=====================

Patients and specimens
----------------------

Archival specimens were obtained from two cohorts of consecutive patients with HCC who underwent curative resection at the Liver Cancer Institute, Zhongshan Hospital, Fudan University, between 2006 and 2007. The patient cohort inclusion and exclusion criteria included (a) accurate pathologic diagnosis of HCC, (b) complete clinicopathologic and follow-up data, (c) no anticancer treatment prior to curative liver resection, and (d) complete formalin-fixed, paraffin-embedded tissues. The histopathological diagnosis was determined according to the World Health Organization criteria. Tumor differentiation was graded using the Edmondson grading system \[[@B23]\]. Tumor staging was based on the 6th edition of the tumor-node-metastasis (TNM) classification of the International Union Against Cancer. Most patients (82.4%) had a hepatitis B virus background, and only two patients had hepatitis C virus. Almost all patients (316 of 318 for the training cohort and 325 of 328 for the validation cohort) were in the Child-Pugh A classification. The clinicopathologic characteristics of the two cohorts are summarized in Additional file [2](#S2){ref-type="supplementary-material"}: Table S1. Ethical approval was obtained from the Zhongshan Hospital Research Ethics Committee, and written informed consent was obtained from each patient.

Follow-up and postoperative treatment
-------------------------------------

The follow-up data were summarized at the end of December 2011, with a median observation time of 52.2 months. The follow-up procedures were described in our previous study \[[@B23],[@B24]\]. Postsurgical patient surveillance was undertaken as previously described \[[@B23],[@B25]\]. OS was defined as the interval between the dates of surgery and death. TTR was defined as the interval between the dates of surgery and the dates of any diagnosed recurrence (intrahepatic recurrence and extrahepatic metastasis). For surviving patients, the data were censored at the date of death or last follow-up.

Tissue microarray and immunohistochemistry
------------------------------------------

Tissue microarray (TMA) was conducted as previously described \[[@B26]-[@B28]\]. Briefly, all samples from the HCC patients were reviewed by three histopathologists and representative areas located away from necrotic and hemorrhagic materials were premarked in the paraffin blocks. Two core biopsies (1 mm in diameter) were taken from each representative tumor tissue and peritumoral tissue to construct the TMA slides. Consecutive sections measuring 4 μm were placed on 3-aminopropyltriethoxysilane-coated slides (Shanghai Biochip Co Ltd, Shanghai, People's Republic of China).

Immunohistochemistry of the paraffin sections was performed using a two-step protocol (Novolink Polymer Detection System, Novocastra) according to the manufacturer's instructions. Briefly, paraffin-embedded sections were deparaffinized and then rehydrated; after heat-induced antigen retrieval, endogenous peroxidases were blocked for 5 min using 0.3% H~2~O~2~, washed twice, and then incubated for 5 min in Serum-Free Protein Block (Novocastra), followed by incubation for 60 min in purified rabbit anti-human 5-hmC and rabbit anti-human IDH2 with DaVinci Green antibody diluent (Biocare Medical). The sections were incubated in a 3, 3-diaminobenzidine solution, counterstained with hematoxylin, dehydrated in ethanol, cleared in xylene, and coverslipped. Negative controls were treated in all assays (with the omission of primary antibodies). The sections were visualized using microscopic observation.

Evaluation of the immunohistochemical findings
----------------------------------------------

IHC staining was assessed by two independent pathologists without knowledge of the clinical and pathologic features of the cases. A negative control array was concurrently undertaken showing \< 1% nuclear staining in all specimens. All specimens were evaluated according to the 0--4 grading criteria (based on the percentage of 5-hmC-positive cells) and 0--3 grading criteria (based on the staining intensity) \[[@B11]\]. The 5-hmC score was calculated as the score of the cell count × the score of intensity. The median 5-hmC score was used as a cut-off in subsequent analyses. For IDH2 quantification, photographs of three representative fields were captured under high-power magnification (200×) using Leica Qwin Plus v3 software; identical settings were used for each photograph. The 5-hmC and IDH2 density were counted using Image-Pro Plus v6.2 software (Media Cybernetics Inc., Bethesda, MD). The integrated optical density of the area positively stained for IDH2 in each photograph was calculated, and its ratio to the total area of each photograph was considered to be the IDH2 density. The median IDH2 density was used as a cut-off in subsequent analyses.

Statistical analysis
--------------------

The data were analyzed with SPSS 19.0 software, as previously described \[[@B23]\]. A *P* value \<0.05 was considered statistically significant.

Results
=======

Immunohistochemical features in TMA
-----------------------------------

Using hematoxylin and eosin staining, the cancer cells were found to be relatively homogenous within a tumor (excluding necrotic, hemorrhagic, and fibrotic components). Representative cases of immunohistochemical staining are shown in Figure [1](#F1){ref-type="fig"}. We observed 5-hmC staining primarily on the nuclei of the tumor cells and hepatocytes; IDH2 staining was observed primarily in the cytoplasm of the HCC cells. Most of the stromal cells were negatively stained, although sporadic positive staining of these cells was observed.

![**Expression of 5-hmC and IDH2 in HCC samples (training cohort, n = 318).** Representative HCC tumor samples show the expression of 5-hmC (brown in the nucleus of HCC cells) and IDH2 (brown in the cytoplasm of HCC cells). Scale bar, 200×, 200 μm.](1756-9966-33-32-1){#F1}

Correlations of 5-hmC and IDH2 expression with clinicopathologic characteristics
--------------------------------------------------------------------------------

The correlations of 5-hmC and IDH2 expression with the clinicopathologic characteristics are shown in Table [1](#T1){ref-type="table"} and Additional file [2](#S2){ref-type="supplementary-material"}: Table S2. In the training cohort, 5-hmC expression correlated with sex (*P* =0.007) and AFP (*P* \<0.001). IDH2 expression only correlated with tumor differentiation (*P* =0.017) (Table [1](#T1){ref-type="table"}). In the validation cohort, 5-hmC expression correlated with sex (*P* =0.003), age (*P* =0.034), AFP (*P* \<0.001), tumor number (*P* =0.02), and TNM stage (*P* =0.009). IDH2 expression correlated with HBsAg (*P* =0.015), AFP (*P* \<0.001), and tumor differentiation (*P* =0.015) (Additional file [2](#S2){ref-type="supplementary-material"}: Table S2). Other clinical characteristics were not directly related to the expression of 5-hmC or IDH2.

###### 

Summary of the correlations of 5-hmC and IDH2 protein expression with clinicopathological features in the training cohort (N = 318)

  **Clinicopathological indexes**              **No. of patients**   **No. of patients**                             
  --------------------------------- ---------- --------------------- --------------------- ------------- ----- ----- -----------
  Sex                               Female     18                    36                    **0.007**     28    26    0.765
                                    Male       141                   123                                 131   133    
  Age(year)                         ≤50        55                    65                    0.247         60    60    1.000
                                    \>50       104                   94                                  99    99     
  HBsAg                             Negative   30                    26                    0.556         28    28    1.000
                                    Positive   129                   133                                 131   131    
  HCV                               Negative   158                   158                   1.000         157   159   0.156
                                    Positive   1                     1                                   2     0      
  AFP                               ≤20        83                    37                    **\<0.001**   58    62    0.644
                                    \>20       76                    122                                 101   97     
  γ-GT(U/L)                         ≤54        87                    81                    0.500         78    90    0.178
                                    \>54       72                    78                                  81    69     
  Liver cirrhosis                   No         32                    26                    0.384         23    35    0.081
                                    Yes        127                   133                                 136   124    
  Tumor number                      Single     131                   134                   0.652         134   131   0.652
                                    Multiple   28                    25                                  25    28     
  Tumor size(cm)                    ≤5         97                    108                   0.197         99    106   0.412
                                    \>5        62                    51                                  60    53     
  Tumor encapsulation               Complete   94                    88                    0.496         93    89    0.650
                                    None       65                    71                                  66    70     
  Microvascular invasion            Absent     113                   107                   0.466         106   114   0.331
                                    Present    46                    52                                  53    45     
  Tumor differentiation             I + II     129                   115                   0.063         113   131   **0.017**
                                    III + IV   30                    44                                  46    28     
  TNM stage                         I          98                    93                    0.567         93    98    0.567
                                    II + III   61                    66                                  66    61     

*Abbreviations*: HBsAg, hepatitis B surface antigen; AFP, α-fetoprotein; γ-GT, γ-glutamyl transferase; TNM, tumor-node-metastasis.

^†^A *P*-value \< 0.05 was considered statistically significant. *P*-values were calculated using the Pearson chi-square test. Boldface type indicates significant values.

Association between combined 5-hmC and IDH2 expression and outcome in the training cohort
-----------------------------------------------------------------------------------------

By the last follow-up in the training cohort (November 2011), 47.2% (150/318) of the patients had suffered a recurrence and 36.5% (116/318) had died. The 1-, 3-, and 5-year OS rates in the cohort were 83.6%, 67.6%, and 63.5% and the cumulative recurrence rates were 32.7%, 46.9%, and 52.8%, respectively. Additionally, we found that the 1-, 3-, and 5-year survival rates of the 5-hmC ^High^ patients were significantly higher than those of the 5-hmC ^Low^ group (87.4% vs. 79.9%, 77.4% vs. 57.9%, and 73.0% vs. 54.1%, respectively) (Figure [2](#F2){ref-type="fig"}a). Similarly, the 5-hmC ^Low^ patients had a poorer prognosis at 1, 3, and 5 years, with higher cumulative recurrence rates than the 5-hmC ^High^ patients (40.3% vs. 25.2%, 56.6% vs. 37.1%, and 61.6% vs. 44.0%, respectively) (Figure [2](#F2){ref-type="fig"}b). We also discovered that the 1-, 3-, and 5-year survival rates of the IDH2 ^High^ patients were significantly higher than those of the IDH2 ^Low^ group (93.7% vs. 73.6%, 76.7% vs. 58.5%, and 71.7% vs. 55.3%, respectively) (Figure [2](#F2){ref-type="fig"}a). Similarly, the IDH2 ^Low^ patients had a poorer prognosis at 1-, 3-, and 5- years, with higher cumulative recurrence rates than the IDH2 ^High^ patients (40.3% vs. 25.2%, 52.2% vs. 41.5%, and 58.5% vs. 47.2%, respectively) (Figure [2](#F2){ref-type="fig"}b). Furthermore, we evaluated the combined effect of 5-hmC and IDH2 expression. We found that the 1-, 3-, and 5-year OS rates in the 5-hmC ^Low^/IDH2 ^Low^ patients were 64.6%, 43.1%, and 43.1%, respectively, which were significantly lower than those in the 5-hmC ^High^/IDH2 ^High^ patients (98.5%, 89.2%, and 86.2%, respectively) (Figure [2](#F2){ref-type="fig"}a). The cumulative recurrence rates in the 5-hmC ^Low^/IDH2 ^Low^ patients were 52.3%, 63.1% and 66.2%, respectively, which were significantly higher than those in the 5-hmC ^High^/IDH2 ^High^ patients (15.4%, 26.2% and 30.8%, respectively) (Figure [2](#F2){ref-type="fig"}b).

![**5-hmC and IDH2 expression and prognostic value in HCC tissue (training cohort, N = 318).** Kaplan-Meier curves depiciting OS **(a)** and TTR **(b)** for 5-hmC expression, IDH2 expression, and combined 5-hmC/IDH2 expression. I, 5-hmC High/IDH2 High; II, 5-hmC Low/IDH2 High; III, 5-hmC High/IDH2 Low; IV, 5-hmC Low/IDH2 Low.](1756-9966-33-32-2){#F2}

Univariate analysis revealed that 5-hmC (*P* \<0.001 and *P* = 0.001), IDH2 (*P* \<0.001 and *P* = 0.006), and 5-hmC/IDH2 combined (*P* \<0.001 and *P* \<0.001) were associated with OS and TTR. γ-GT, tumor number, tumor size, microvascular invasion, and TNM stage were predictors of OS and TTR. Moreover, AFP was only associated with OS, and liver cirrhosis was only associated with TTR (Table [2](#T2){ref-type="table"}).

###### 

Summary of univariate and multivariate analyses of 5-hmC and IDH2 protein expression associated with survival and recurrence in the training cohort (N = 318)

                 **Factor**                    **OS**      **TTR**                                                                     
  ----------------------------------------- ------------- --------- --------------- ------------- ------------- ------- -------------- -------------
            Sex (female vs. male)               0.959                                    NA           0.083                                 NA
          Age, years (≤50 vs. \>50)             0.772                                    NA           0.597                                 NA
        HBsAg (negative vs. positive)           0.983                                    NA           0.491                                 NA
          AFP, ng/ml (≤20 vs. \>20)           **0.041**     1.893    1.257--2.852     **0.002**       0.230                                 NA
          γ-GT, U/L (≤54 vs. \>54)            **0.006**     1.619    1.118--2.343     **0.011**     **0.003**    1.547   1.138--2.102    **0.005**
        Liver cirrhosis (no vs. yes)            0.077                                    NA         **0.009**    1.824   1.135--2.930    **0.013**
     Tumor number (single vs. multiple)       **0.003**                                  NS         **0.002**    1.651   1.135--2.402    **0.009**
         Tumor size, cm (≤5 vs. \>5)          **0.009**                                  NS         **0.041**                               NS
   Tumor encapsulation (complete vs. none)      0.261                                    NA           0.166                                 NA
     Microvascular invasion (no vs. yes)      **0.003**                                  NS         **0.001**    1.775   1.287--2.448   **\<0.001**
   Tumor differentiation (I-II vs. III-IV)      0.138                                    NA           0.053                                 NA
          TNM stage (I vs. II III)           **\<0.001**    2.048    1.412--2.971    **\<0.001**   **\<0.001**   1.649   1.134--2.397    **0.009**
            5-hmC (low vs. high)             **\<0.001**    0.316    0.211--0.472    **\<0.001**    **0.001**    0.462   0.335--0.636   **\<0.001**
             IDH2 (low vs. high)             **\<0.001**    0.405    0.275--0.594    **\<0.001**    **0.006**    0.591   0.432--0.810    **0.001**
        Combination of 5-hmC and IDH2        **\<0.001**                             **\<0.001**   **\<0.001**                          **\<0.001**
                 I versus II                  **0.002**     3.987    1.890--8.413    **\<0.001**    **0.001**    2.651   1.576--4.461   **\<0.001**
                I versus III                  **0.002**     3.359    1.607--7.025     **0.001**     **0.003**    2.098   1.247--3.530    **0.005**
                 I versus IV                 **\<0.001**    8.908    4.215--18.825   **\<0.001**   **\<0.001**   3.891   2.270--6.671   **\<0.001**

*Abbreviations*: OS, overall survival; TTR time to recurrence; AFP, α-fetoprotein; γ-GT, γ-glutamyl transferase; TNM, tumor-node-metastasis; CI, confidence interval; NA, not adopted; NS, not significant.

^†^Cox proportional hazards regression. Boldface type indicates significant values.

I, 5-hmC ^High^/IDH2 ^High^; II, 5-hmC ^Low^/IDH2 ^High^; III, 5-hmC ^High^/IDH2 ^Low^; IV, 5-hmC ^Low^/IDH2 ^Low^.

The individual clinicopathological features that presented significance in the univariate analysis were adopted as covariates in a multivariate Cox proportional hazards model for further analysis. 5-hmC and IDH2 were prognostic indicators of OS (*P* \<0.001 and *P* \<0.001) and TTR (*P* \<0.001 and *P* =0.001). When 5-hmC was combined with IDH2, we found that 5-hmC/IDH2 was also an independent prognostic indicator of both OS (*P* \<0.001) and TTR (*P* \<0.001) (Figure [2](#F2){ref-type="fig"} and Table [2](#T2){ref-type="table"}).

Validation analysis of the better outcome of patients in the validation cohort with 5-hmC ^High^/IDH2 ^High^ expression
-----------------------------------------------------------------------------------------------------------------------

To validate our findings of better outcomes in patients with 5-hmC ^High^/IDH2 ^High^ expression, we studied a validation cohort that included 328 surgically resected HCC tumors. Briefly, we found that the 1- and 3-year OS rates in the 5-hmC ^Low^/IDH2 ^Low^ patients were 66.3% and 46.3%, respectively, which were significantly lower than those in the 5-hmC ^High^/IDH2 ^High^ patients (97.0% and 79.0%, respectively) (Figure [3](#F3){ref-type="fig"}a). The cumulative recurrence rates in the 5-hmC ^Low^/IDH2 ^Low^ patients were 52.5% and 71.3%, respectively, which were significantly higher than those in the 5-hmC ^High^/IDH2 ^High^ patients (19.0% and 36.0%, respectively) (Figure [3](#F3){ref-type="fig"}b).

![**5-hmC and IDH2 expression and prognostic value in HCC tissue (validation cohort, N = 328).** Kaplan-Meier curves depiciting OS **(a)** and TTR **(b)** for 5-hmC expression, IDH2 expression, and combined 5-hmC/IDH2 expression. I, 5-hmC ^High^/IDH2 ^High^; II, 5-hmC ^Low^/IDH2 ^High^; III, 5-hmC ^High^/IDH2 ^Low^; IV, 5-hmC ^Low^/IDH2 ^Low^.](1756-9966-33-32-3){#F3}

Univariate analysis revealed that 5-hmC (*P* \<0.001 and *P* \<0.001), IDH2 (*P* =0.001 and *P* \<0.001), and 5-hmC/IDH2 combined (*P* \<0.001 and *P* \<0.001) were associated with OS and TTR. In a multivariate Cox proportional hazards model, 5-hmC and IDH2 were prognostic indicators of OS (*P* =0.005 and *P* =0.005) and TTR (*P* =0.008 and *P* =0.02). When 5-hmC and IDH2 were combined, we found that 5-hmC/IDH2 was also an independent prognostic indicator of both OS (*P* =0.007) and TTR (*P* =0.009) (Additional file [2](#S2){ref-type="supplementary-material"}: Table S3).

Discussion
==========

To date, the available data on 5-hmC and IDH2 in HCC have been limited. In this study, we investigated the clinical relevance of 5-hmC and IDH2 protein expression in two large cohorts (n = 646) of surgically resected HCCs with 318 cases and 328 cases, respectively.

We determined that high 5-hmC expression was significantly associated with favorable features in HCC patients. This finding may be substantiated by the fact that aggressive histopathological characteristics, including a high AFP level was significantly more frequent in patients with low 5-hmC expression than in those with high expression in training cohort. And a high AFP level, more tumor number, and an advanced TNM staging of HCC were more detected in those patients with low 5-hmC expression in validation cohort. This indicated that 5-hmC may be a powerful prognostic indicator in HCC. 5-hmC, an oxidation product of 5mC via the TET family (which consists of TET1, -2, and -3), is abundant in ES cells and adult neural cells \[[@B8]\]. The relationship between 5-hmC and tumors is emerging through a number of studies \[[@B8],[@B11],[@B29]\]. In liver cancer research, 5-hmC expression was decreased in liver cancer compared with the surrounding normal tissue \[[@B14],[@B15]\]. Although previous studies have addressed 5-hmC protein expression using IHC in archived HCC tissues, the number of cases is limited and lacks further validation. Our study represents the largest analysis of 5-hmC protein expression in HCC.

We also detected significant correlations between low IDH2 expression and HBsAg background, a high level of AFP, and low-grade tumor differentiation. IDH2, an IDH (which convert isocitrate to α-KG), is frequently mutated in cancer, particularly in secondary glioblastoma \[[@B30]\], cytogenetically normal acute myeloid leukemia (AML) \[[@B31]\], cartilaginous tumors \[[@B32]\], and intrahepatic cholangiocarcinoma \[[@B33]\]. The pathophysiological function of the *R*-enantiomer of 2-hydroxylglutarate (*R*-2-HG) is the driving force of IDH1/2 mutation-induced tumorigenesis \[[@B22]\]. In melanoma, IDH2 is frequently downregulated, and the overexpression of IDH2 in a zebrafish melanoma model has been shown to increase the level of 5-hmC, resulting in prolonged tumor-free survival \[[@B11]\]. In our group, the preliminary experimental results indicated a tumor suppressor role for IDH2 in HCC (unpublished data); however, the expression of mutated IDH2, the mechanisms of IDH2 mutation, and the precise role of IDH2 in HCC remain under investigation.

One of most notable findings of our study was that the expression of 5-hmC or IDH2 alone, as well as the expression of the combination of 5-hmC and IDH2, was significantly correlated with OS and TTR in two cohorts. Thus, we made a direct comparison of prognosis between four subgroups (5-hmC ^High^/IDH2 ^High^, 5-hmC ^Low^/IDH2 ^High^, 5-hmC ^High^/IDH2 ^Low^, and 5-hmC ^Low^/IDH2 ^Low^) in the training cohort. As expected, patients with 5-hmC ^High^/IDH2 ^High^ expression had a significantly better OS and TTR than the patients in the other 3 groups in both univariate and multivariate analyses. These interesting observations were confirmed in a second cohort (validation cohort) that exhibited clinical-pathological features similar to the first cohort (training cohort).

In addition to genetic alterations, epigenetic alterations were also considered to participate in carcinogenesis \[[@B34]\]. It is also plausible that the two mechanisms can coexist and interact, giving birth to the observed hot-spot tumor heterogeneity \[[@B35],[@B36]\]. The mechanisms of this interaction are currently the chief investigational pursuit of our laboratory. In this study, we determined the prognostic value of 5-hmC and IDH2 in HCC; further investigations are in progress.

The major limitation of the present work was its retrospective nature. Moreover, it is noteworthy that most HCC patients in China have a hepatitis B virus-positive background, which differs from studies in Japan, Europe, and the United States.

To the best of our knowledge, this is the first paper demonstrating the implications of 5-hmC and IDH2 in HCC. Our findings indicate that a high expression of 5-hmC and IDH2 predicts comparably less aggressive tumor behavior. Importantly, 5-hmC expression (particularly when combined with IDH2 expression) enables us to more accurately predict the true prognosis of HCC patients. Moreover, given the proposed epigenetic nature of 5-hmC and IDH2, the therapeutic manipulation of 5-hmC and IDH2 will assist in guiding clinical strategies.

Conclusions
===========

In summary, 5-hmC and IDH2 correlate with less aggressive tumor behavior in HCC. Low 5-hmC or IDH2 expression alone and combined 5-hmC and IDH2 expression were associated with lower OS rates and higher cumulative recurrence rates. When 5-hmC and IDH2 are considered together, they serve as a prognostic marker in patients with surgically resected HCCs.
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